Incyte Corporation (Nasdaq: INCY) today announced its support of the
first national Myelofibrosis Awareness Day, which will be held on Sept.
20, 2012. The inaugural recognition day is being led by the MPN
Coalition, a group of patient advocacy organizations that have come
together to help people living with myelofibrosis (MF). MF belongs to a
group of diseases called myeloproliferative neoplasms (MPNs), and is a
progressive, potentially life-threatening blood cancer with limited
treatment options.1 Patients with MF suffer a high disease
burden characterized by bone marrow failure, enlarged spleen
(splenomegaly) and debilitating symptoms including fatigue, severe
itching (pruritus), night sweats, bone pain, and early satiety (a
feeling of fullness), leading to impaired quality of life.2
“Volunteers across the country are promoting Sept. 20 as Myelofibrosis
Awareness Day to connect organizations, doctors and individuals affected
by MF to ensure that patients and their families have the necessary
information, support and resources to better manage this disease,”
stated Ann Brazeau, chairperson of the MPN Coalition and Vice President
of Development of the MPN Research Foundation. “The theme for the day is
‘Empower,’ and those affected by MF are being encouraged to become more
knowledgeable about the disease, to be active and engaged partners in
their care, and to gain strength as part of a group of individuals
facing similar challenges.”
“With Myelofibrosis Awareness Day, we’re encouraged to see so many
important organizations come together to rally around such an important
cause. Their efforts will help to bring greater understanding about this
rare disease to physicians and help patients with MF become more
empowered in dealing with their disease,” stated Paul A. Friedman, MD,
President and Chief Executive Officer, Incyte.
Launching the program in September, which is Blood Awareness Month,
provides an opportunity to further the efforts of the MPN Coalition in
educating and building support for patients with MF. Myelofibrosis
Awareness Day will serve as the kickoff for many awareness activities,
which will continue throughout the year.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on discovering, developing and commercializing
proprietary small molecule drugs for inflammation and oncology,
including products for myelofibrosis. For additional information about
Incyte, please visit www.incyte.com.
Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring
system for primary myelofibrosis based on a study of the International
Working Group for Myelofibrosis Research and Treatment. Blood.
Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and
quality of life in myeloproliferative disorders (MPDs): an
international internet-based survey of 1179 MPD patients. Cancer.